Skip to main content
Erschienen in: International Journal of Hematology 6/2015

01.06.2015 | Original Article

Analysis of clinical characteristics and prognostic factors for angioimmunoblastic T-cell lymphoma

verfasst von: Yoshihiro Kameoka, Naoto Takahashi, Shigeki Itou, Masaaki Kume, Hideyoshi Noji, Yuichi Kato, Yoshikazu Ichikawa, Osamu Sasaki, Mutsuhito Motegi, Atsushi Ishiguro, Hiroyuki Tagawa, Kenichi Ishizawa, Yoji Ishida, Ryo Ichinohasama, Hideo Harigae, Kenichi Sawada

Erschienen in: International Journal of Hematology | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Angioimmunoblastic T-cell lymphoma (AITL) is a distinct peripheral T-cell lymphoma entity exhibiting peculiar clinical features and poor prognosis. Its clinical characteristics and prognostic factors are not well established. To clarify the clinical characteristics and prognostic features of AITL, we conducted a multicenter, retrospective study. Fifty-six patients were enrolled. The median patient age was 68 years. Immunohistochemical examinations of tumor cells showed positivity for CD10 and T-cell markers, and chromosomal examination detected several types of abnormalities. More than 80 % of patients show advanced disease at diagnosis and poor prognostic scores. A high proportion of patients showed accompanying B symptoms, splenomegaly, and hepatomegaly at diagnosis. The 5-year overall survival (OS) rate was 48 % and progression-free survival was 25 %. Univariate analysis revealed higher age, fever, poor performance status, anemia, and low albumin level to be poor prognostic factors for OS. In addition to these factors, both IPI and PIT were also predictive of OS. Multivariate analysis indicated only a low level of serum albumin to be a significant prognostic factor for OS. Serum albumin may be one of the important prognostic factors for AITL. Further investigation is needed to confirm these results.
Literatur
1.
Zurück zum Zitat Mourad N, Mounier N, Brière J, Raffoux E, Delmer A, Feller A, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood. 2008;111:4463–70.PubMedCentralPubMedCrossRef Mourad N, Mounier N, Brière J, Raffoux E, Delmer A, Feller A, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood. 2008;111:4463–70.PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Rüdiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 2002;13:140–9.PubMedCrossRef Rüdiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 2002;13:140–9.PubMedCrossRef
3.
Zurück zum Zitat de Leval L, Rickman DS, Thielen C, Reynies Ad, Huang YL, Delsol G, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109:4952–63.PubMedCrossRef de Leval L, Rickman DS, Thielen C, Reynies Ad, Huang YL, Delsol G, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109:4952–63.PubMedCrossRef
4.
Zurück zum Zitat Attygalle A, Al-Jehani R, Diss TC, Munson P, Liu H, Du MQ, et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood. 2002;99:627–33.PubMedCrossRef Attygalle A, Al-Jehani R, Diss TC, Munson P, Liu H, Du MQ, et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood. 2002;99:627–33.PubMedCrossRef
5.
Zurück zum Zitat Dupuis J, Boye K, Martin N, Copie-Bergman C, Plonquet A, Fabiani B, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol. 2006;30:490–4.PubMedCrossRef Dupuis J, Boye K, Martin N, Copie-Bergman C, Plonquet A, Fabiani B, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol. 2006;30:490–4.PubMedCrossRef
6.
Zurück zum Zitat Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2006;30:802–10.PubMedCentralPubMedCrossRef Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2006;30:802–10.PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma:analysis of the international peripheral T-cell lymphoma project. J Clin Oncol. 2013;31:240–6.PubMedCentralPubMedCrossRef Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma:analysis of the international peripheral T-cell lymphoma project. J Clin Oncol. 2013;31:240–6.PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Frizzera G, Moran EM, Rappaport H. Angio-immunoblastic lymphadenopathy with dysproteinaemia. Lancet. 1974;1:1070–3.PubMedCrossRef Frizzera G, Moran EM, Rappaport H. Angio-immunoblastic lymphadenopathy with dysproteinaemia. Lancet. 1974;1:1070–3.PubMedCrossRef
9.
Zurück zum Zitat Siegert W, Agthe A, Griesser H, Schwerdtfeger R, Brittinger G, Engelhard M, et al. Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. Ann Intern Med. 1992;117:364–70.PubMedCrossRef Siegert W, Agthe A, Griesser H, Schwerdtfeger R, Brittinger G, Engelhard M, et al. Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. Ann Intern Med. 1992;117:364–70.PubMedCrossRef
10.
Zurück zum Zitat Siegert W, Nerl C, Meuthen I, Zahn T, Brack N, Lennert K, et al. Recombinant human interferon-alpha in the treatment of angioimmunoblastic lymphadenopathy:results in 12 patients. Leukemia. 1991;5:892–5.PubMed Siegert W, Nerl C, Meuthen I, Zahn T, Brack N, Lennert K, et al. Recombinant human interferon-alpha in the treatment of angioimmunoblastic lymphadenopathy:results in 12 patients. Leukemia. 1991;5:892–5.PubMed
11.
Zurück zum Zitat Advani R, Warnke R, Sikic BI, Horning S. Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine. Ann Oncol. 1997;8:601–3.PubMedCrossRef Advani R, Warnke R, Sikic BI, Horning S. Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine. Ann Oncol. 1997;8:601–3.PubMedCrossRef
12.
Zurück zum Zitat Pautier P, Devidas A, Delmer A, Dombret H, Sutton L, Zini JM, et al. Angioimmunoblastic-like T-cell non Hodgkin’s lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma. 1999;32:545–52.PubMed Pautier P, Devidas A, Delmer A, Dombret H, Sutton L, Zini JM, et al. Angioimmunoblastic-like T-cell non Hodgkin’s lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma. 1999;32:545–52.PubMed
13.
Zurück zum Zitat Siegert W, Nerl C, Agthe A, Engelhard M, Brittinger G, Tiemann M, et al. Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma:prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann Oncol. 1995;6:659–64.PubMed Siegert W, Nerl C, Agthe A, Engelhard M, Brittinger G, Tiemann M, et al. Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma:prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann Oncol. 1995;6:659–64.PubMed
14.
Zurück zum Zitat A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987–94. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987–94.
15.
Zurück zum Zitat Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474–9.PubMedCrossRef Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474–9.PubMedCrossRef
16.
Zurück zum Zitat Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.PubMed Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.PubMed
17.
Zurück zum Zitat Cheson BD, Pfistner B, Juweid ME, Shipp MA, Fisher RI, Connors JM, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.PubMedCrossRef Cheson BD, Pfistner B, Juweid ME, Shipp MA, Fisher RI, Connors JM, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.PubMedCrossRef
18.
Zurück zum Zitat Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef
19.
Zurück zum Zitat Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–70.PubMed Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–70.PubMed
20.
Zurück zum Zitat Tokunaga T, Shimada K, Yamamoto K, Chihara D, Ichihashi T, Oshima R, et al. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood. 2012;119:2837–43.PubMedCrossRef Tokunaga T, Shimada K, Yamamoto K, Chihara D, Ichihashi T, Oshima R, et al. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood. 2012;119:2837–43.PubMedCrossRef
21.
Zurück zum Zitat Watanabe T, Kinoshita T, Itoh K, Yoshimura K, Ogura M, Kagami Y, et al. Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas. Leuk Lymphoma. 2010;51:813–21.PubMedCrossRef Watanabe T, Kinoshita T, Itoh K, Yoshimura K, Ogura M, Kagami Y, et al. Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas. Leuk Lymphoma. 2010;51:813–21.PubMedCrossRef
22.
Zurück zum Zitat Lee SS, Rüdiger T, Odenwald T, Roth S, Starostik P, Müller-Hermelink HK. Angioimmunoblastic T cell lymphoma is derived from mature T-helper cells with varying expression and loss of detectable CD4. Int J Cancer. 2003;103:12–20.PubMedCrossRef Lee SS, Rüdiger T, Odenwald T, Roth S, Starostik P, Müller-Hermelink HK. Angioimmunoblastic T cell lymphoma is derived from mature T-helper cells with varying expression and loss of detectable CD4. Int J Cancer. 2003;103:12–20.PubMedCrossRef
23.
Zurück zum Zitat Pangalis GA, Moran EM, Nathwani BN, Zelman RJ, Kim H, Rappaport H. Angioimmunoblastic lymphadenopathy. Long-term follow-up study. Cancer. 1983;52:318–21.PubMedCrossRef Pangalis GA, Moran EM, Nathwani BN, Zelman RJ, Kim H, Rappaport H. Angioimmunoblastic lymphadenopathy. Long-term follow-up study. Cancer. 1983;52:318–21.PubMedCrossRef
24.
Zurück zum Zitat Archimbaud E, Coiffier B, Bryon PA, Vasselon C, Brizard CP, Viala JJ. Prognostic factors in angioimmunoblastic lymphadenopathy. Cancer. 1987;59:208–12.PubMedCrossRef Archimbaud E, Coiffier B, Bryon PA, Vasselon C, Brizard CP, Viala JJ. Prognostic factors in angioimmunoblastic lymphadenopathy. Cancer. 1987;59:208–12.PubMedCrossRef
25.
Zurück zum Zitat Lee SM, Ryder WD, Clemons MJ, Morgenstern GR, Chang J, Scarffe JH, et al. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin’s lymphoma. Bone Marrow Transpl. 1999;24:271–7.CrossRef Lee SM, Ryder WD, Clemons MJ, Morgenstern GR, Chang J, Scarffe JH, et al. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin’s lymphoma. Bone Marrow Transpl. 1999;24:271–7.CrossRef
26.
Zurück zum Zitat Federico M, Vitolo U, Zinzani PL, Chisesi T, Clò V, Bellesi G, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi Blood. 2000;95:783–9. Federico M, Vitolo U, Zinzani PL, Chisesi T, Clò V, Bellesi G, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi Blood. 2000;95:783–9.
27.
Zurück zum Zitat Ibrahim EM, Ezzat AA, El-Weshi AN, Martin JM, Khafaga YM, Al Rabih W, et al. Primary intestinal diffuse large B-cell non-Hodgkin’s lymphoma: clinical features, management, and prognosis of 66 patients. Ann Oncol. 2001;12:53–8.PubMedCrossRef Ibrahim EM, Ezzat AA, El-Weshi AN, Martin JM, Khafaga YM, Al Rabih W, et al. Primary intestinal diffuse large B-cell non-Hodgkin’s lymphoma: clinical features, management, and prognosis of 66 patients. Ann Oncol. 2001;12:53–8.PubMedCrossRef
28.
Zurück zum Zitat Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, Hanada S, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol. 2012;30:1635–40.PubMedCrossRef Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, Hanada S, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol. 2012;30:1635–40.PubMedCrossRef
29.
Zurück zum Zitat Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339:1506–14.PubMedCrossRef Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339:1506–14.PubMedCrossRef
Metadaten
Titel
Analysis of clinical characteristics and prognostic factors for angioimmunoblastic T-cell lymphoma
verfasst von
Yoshihiro Kameoka
Naoto Takahashi
Shigeki Itou
Masaaki Kume
Hideyoshi Noji
Yuichi Kato
Yoshikazu Ichikawa
Osamu Sasaki
Mutsuhito Motegi
Atsushi Ishiguro
Hiroyuki Tagawa
Kenichi Ishizawa
Yoji Ishida
Ryo Ichinohasama
Hideo Harigae
Kenichi Sawada
Publikationsdatum
01.06.2015
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 6/2015
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-015-1763-7

Weitere Artikel der Ausgabe 6/2015

International Journal of Hematology 6/2015 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.